Survived ten years with ovarian cancer taking Olaparib

The drug olaparib could become an early treatment option for some women with ovarian cancer, according to new findings from a large clinical trial. Lynparza has been approved as maintenance therapy and treatment for patients with advanced ovarian cancer who have received multiple forms of chemotherapy, results fromthe SOLO-1 trial showed that the drug can significantly delay the recurrence of the cancer after first-line chemotherapy.

Olaparib contains the active ingredientolaparib. It is a PARP inhibitor that can be used alone or in combination with other cancer drugs, such as bevacizumab for ovarian cancer. These proteins help repair damaged DNA. Because BRCA mutations also impede DNA repair, further inhibiting this process with olaparib can lead to the death of cancer cells carrying BRCA mutations. In the studythree years after randomization, the progression-free survival rate was 60% in the olaparib group and 27% in the placebo group. Researchers determined that treatment with olaparib reduced the risk of progression or death by 70%, and the median progression-free survival in the placebo group was approximately 14 months. Longer follow-up is needed to determine median progression-free survival in the olaparib group, but the current analysis suggests it may be longer than 4 years.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.